Neoadyuvancia
Quimioterapia de Inducción
La quimioterapia como tratamiento útil en pacientes portadores de distintas neoplasias fue variando sus indicaciones, combinaciones y vías de administración a lo largo del tiempo.
Autor/a: Por el Dr. Adrián Huñis*
Indice
1. Bibliografía
2. Curriculum
3. El Modelo de Goldie y Coldman
4. El Concepto de la Intensidad de Dosis
5. Mecanismos de Resistencia Celular a Citostáticos
6. Historia de la Neoadyuvancia
7. Fundamentos Biológicos del Uso de la Quimioterapia
8. Bases de cinética celular
9. Introducción y Generalidades
2) FREI. E,; MILDES, D.; CLARK, J.R.: "CLINICAL AND SCIENTIFIC CONSIDERATIONS IN PREOPERATIVE CHOMOTHERAPY (NEOADYUVANT)". Recent Results in Cancer Research, Vol. 103, 1986: 1-5.
3) HARRIS, D.; MASTRANGELO, M.: "THEORY AND APPLICATION OF EARLY SYSTEMIC THERAPY". Seminars in Oncology, 18 (6), Dic. 1991: 493-503.
4) DE VITA, V.T.: "CELL KINETICS AND THE CHEMOTHERAPY OF CANCER". Cancer Chemother. Rep., 2: 23, 1971.
5) YOUNG: "CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO". Cell and Tissue Kinet., 3: 285, 1970.
6) GORDON STEEL, G.: "CYTOKINETICS OF NEOPLASIA ". Cancer Medicine, pag. 125. Lea & Febiger. Filadelfia, 1973.
7) MUMPREY, R.M. Y BARRANCO, S. C.: " CELLULAR PHARMACOLOGY". Pharmacologial Basis of Cancer Chemotherapy, pag. 85. University of Texas, Anderson Hospital. Williams & Wilkins. Baltimore, 1975.
8) SKIPPER , H.E. y SCHABEL, F.M., Jr. "QUANTITATIVE AND CYTOKINETIC STUDIES IN EXPERIMENTAL TUMOR MODELS". Cáncer Medicine, pag. 629.Lea &Febiger. Filadelfia, 1973.
9) SKIPPER, H.E.: "PHARMACOLOGICAL BASIS OF CANCER CHEMOTHERAPY: CLOSING REMARKES". Pharmacological Basis of Cancer Chemotherapy, pag. 713. University of Texas. Anderson Hospital. WILLIAMS & Wilkins. Baltimore, 1975
10) GORDON STEEL, G.: "CELL KINETICS AND CELL SURVIVAL". Medical Oncology, pag. 49. Blackwell Scientific Publications. Oxford, 1975
11) MENDELSON, M.L.:"THE GROWTH FRACTION A NEW CONCEPT APLIED TO TUMORS". Science, 132: 1496,1960.
12) SKIPPER ; H.E.: "BIOCHEMICAL, PHARMACOLOGIC,TOXICOLOGIC,KINETIC AND CLINICAL (Subhuman and human) RELATIONSHIPS". Cancer (Philad.), 21: 600,1968.
13) SUGARBAKER, E.V., KETCHMAN, A.S. y COHEN, A.M.: "STUDIES OF DORMANT TUMOR CELLS". Cancer (Philad.), 28: 545,1971.
14) STEEL, G.G: "CELL LOSS FROM EXPERIMENTAL TUMORS". Cell Tissue Kinet., 1: 193,1968
15) SCHABEL, F.M., Jr.: "CONCEPTS FOR SYSTEMIC TREATMENT OF MICROMETASTASES". Cancer (Philad), 35: 15,1975.
16) SKIPPER, H.E.: "THE CELL CYCLE AND CHEMOTHERAPY OF CANCER IN BASERGA R(ed): THE CELL CYCLE AND CANCER". New York, NY, Marcel Dekker, Inc., 1971. Pp 358-387
17) TUBIANA, M., MALAISE , EP.: "GROWTH RATE AND CELL KINETICS IN HUMAN TUMORS: SOME PROGNOSTIC AND THERAPEUTIC IMPLICATIONS, IN SYMINGTON".T, CARTE RL (eds): Scientific Foundations of Oncology. Chicago, IL, Yearbool Medical Publishers, 1976, pp 126-136
18) STEEL,G.G: "GROWTH KINETICS O TUMOURS". Oxford, Clarendon Press,1977, p204.
19) GOLDIE, J.H.: COLDMAN, A.J.: "CURRENT STATUS OF MUTATIONAL THEORIES FOR THE ORIGIN OF DRUG RESISTANCE". Neoplasms: Adjuvant therapy of cancer VI. Salmon SE (ed.) Philadelphia. PA, Saunders, 1990: 21-5.
20) GOLDIE, J.H., COLDMAN, A.J.:"QUANTITATIVE MODEL FOR MULTIPLE LEVELS OF DRUG RESISTANCE IN CLINICAL TUMORS". Cancer Treat. Rep. 67, 1983: 923-31
21) YARBRO, J.: "FUTURE POTENTIAL OF ADJUVANT AND NEOADYUVANT THERAPY". Seminars in Oncology, 18 (6), Dic. 1991: 613-619
22) FREI, E III, CANELLOS, GP.: "DOSE:A CRITICAL FACTOR IN CANCER CHEMOTHERAPY". Am.J.Med., 69: 585-594,1980.
23) PINKEL, D., HERNANDEZ, K., BORELLA, L., et al: "DRUG DOSAGE AND REMISSION DURATION IN CHILDHOOD LYMPHOCYTIC LEUKEMIA". Cancer 27: 247-256,1971.
24) DE VITA, VT.: "DOSE-RESPONSE IS ALIVE AND WELL". J.Clin.Oncol., 4: 1157-1159,1986.
25) HYRNIUK, W.M., BONADONNA, G., VALAGUSSA, P.: "THE EFECT OF DOSE INTENSITY IN ADJUVANT CHEMOTHERAPY" . Salmon SE (ed): Adjuvant therapy of cancer V.Orlando, FL, Grune and Statton, 1987, pp 13-23.
26) BECK, WT., MUELLER, TJ., TANZER, LR.:"ALTERED SURFACE MEMBRANE GLYCOPROTEINS IN VINCA ALKALOID RESISTANT LEUKEMIC LYMPHOBLASTS". Cancer Res. 39: 2070-2076, 1979
27) RIORDAN, JR., LING V:"GENETIC AND BIOCHEMICAL CHARACTERIZATION OF MULTIDRUG RESISTANCE". Pharmacol Ther. 28: 51-75, 1985
28) GERLACH, JH., KARTNER, N., BELL DR:, et al: "MULTIDRUG RESISTANCE". Cancer Surv. 5: 25-46, 1986
29) FIDLER, IJ., KRIPKE, ML.:"METASTASIS RESULTS FROM PREEXISTING VARIANT CELLS WITHIN A MALIGMANT TUMOR". Science 197: 893-895, 1977
30) FIDLER, IJ.: "TUMOR HETEROGENEITY AND BIOLOGY OF CANCER INVASION AND METASTASIS". Cancer Res, 38: 2651-2660,1978